Immune Classification Tool for Determining Survival Outcomes in Cancer
개요
출원인
London Health Sciences Centre Research Inc.; The Regents of the University of California
발명자
Yu Fan Zeng; Anthony Nichols; John Barrett; Paul Boutros; Joseph Mymryk
IPC 분류
CPC 분류
An immune classification tool useful for determining survival outcomes in cancer patients based on the abundance in gene expression of CD3E, ZAP70 and IRF4 in a cancer tissue sample. The immune classification tool is able to stratify cancer patients, including HPV+HNSCC, HPV−HNSCC and cervical cancer patients, into the three immune groups (immune rich, immune desert, and mixed) that are strongly associated with disease-free survival.
원문 (중국어)
An immune classification tool useful for determining survival outcomes in cancer patients based on the abundance in gene expression of CD3E, ZAP70 and IRF4 in a cancer tissue sample. The immune classification tool is able to stratify cancer patients, including HPV+HNSCC, HPV−HNSCC and cervical cancer patients, into the three immune groups (immune rich, immune desert, and mixed) that are strongly associated with disease-free survival.